Results 11 to 20 of about 18,164 (153)
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. [PDF]
Mol OncolWNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Balaseviciute U +17 more
europepmc +2 more sources
Annals of Hepatology, 2022 Introduction and Objectives: Liver transplantation (LT) is the treatment for end-stage liver disease that may present graft rejection. Conditioning with natural products has shown great therapeutic utility, specifically against ischemia-reperfusion (IR).
P. Cordero- Pérez +6 more
doaj +1 more source
Tendencias de mortalidad y riesgo de muerte por cáncer de hígado en México, 2000-2013 [PDF]
Cirugía y Cirujanos, 2021 Introduction: Liver cancer (LC) is a public health problem in the world, since is the second leading cause of death and Mexico is no exception, in 2013 the LC ranked fourth of mortality among malignancies. Material and methods: The records of mortality associated to LC for the period 2000-2013 were obtained from National Institute of Statistics and ...
openaire +2 more sources
Annals of Hepatology, 2021 Introduction: COVID-19 affects the liver, causing alteration in liver biochemistry tests such as aspartate transferase (AST), alanine transferase (ALT), alkaline phosphatase (ALP), total bilirubin and albumin.
Ivania Marín Dueñas +9 more
doaj +1 more source
Hepatology Communications, EarlyView., 2022 Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo +19 more
wiley +1 more source
DETERMINATION OF LEUKOCYTE PROFILE IN CHRONIC ALCOHOL CONSUMPTION
Annals of Hepatology, 2022 Introduction and objective: Chronic alcohol consumption can induce Alcoholic Liver Disease (ALD) promoting biological alterations and liver damage; however, the immunological changes usually are underestimated.
E.A. Alamo-Capula +12 more
doaj +1 more source
Annals of Hepatology, 2022 Introduction and Objectives: Dysregulation of pro-inflammatory/anti-inflammatory cytokines and oxidative stress markers has been reported in Non-Alcoholic Steatohepatitis (NASH) and alcoholic steatohepatitis (ASH); however, in the disease recently known,
L. Torres-González +8 more
doaj +1 more source
Annals of Hepatology, 2022 Introduction and Objectives: The virus of hepatitis C (HCV) and alcoholic liver disease (ALD), are of the main causes of liver disease mortality. There is a need to determine biomarkers, serum cytokines are candidates since they participate in the ...
M. Hernandez-Santillan +12 more
doaj +1 more source
Esteatosis hepática (hígado graso) [PDF]
, 2022 [es] Folleto informativo para pacientes sobre Esteatosis hepática (hígado graso)[glg] Folleto informativo para pacientes sobre Esteatosis hepática (fígado ...
core +1 more source
OXIDATIVE DAMAGE MARKERS IN ALCOHOLIC HEPATITIS
Annals of Hepatology, 2022 Introduction and objective: Alcohol hepatitis (AH) is a clinical syndrome in patients with excessive and chronic alcohol consumption. Ethanol metabolism produces free radicals: reactive oxygen species (ROS) and reactive nitrogen species (RNS).
S. Sánchez-Valle +11 more
doaj +1 more source